Evidence map›Paper›PMID 25896263›Full record

ArticleCardiovascular diabetology2015

The FAT expandability (FATe) Project: Biomarkers to determine the limit of expansion and the complications of obesity.

Elena Torres-Perez, Monica Valero, Beatriz Garcia-Rodriguez, Yolanda Gonzalez-Irazabal, Pilar Calmarza, Luisa Calvo-Ruata, Carmen Ortega, Maria Pilar Garcia-Sobreviela, Alejandro Sanz-Paris, Jose Maria Artigas and 2 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Cardiovascular diabetology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Metabolically healthy obesity: a friend or foe?The Korean journal of internal medicine · 2017
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Elena Torres-PerezAdipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain. etorresp.iacs@aragon.es.
Monica ValeroUnidad de Cirugía, Hospital Royo Villanova, Zaragoza, Spain. mvalsaba@hotmail.com.
Beatriz Garcia-RodriguezServicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. bea_garcia_rodriguez@hotmail.com.
Yolanda Gonzalez-IrazabalServicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. yolgonira@gmail.com.
Pilar CalmarzaServicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. mpcalmarza@salud.aragon.es.
Luisa Calvo-RuataServicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. mlcalvo@salud.aragon.es.
Carmen OrtegaServicio de Bioquímica Clínica, Hospital Universitario Miguel Servet, Zaragoza, Spain. cortegama@salud.aragon.es.
Maria Pilar Garcia-SobrevielaAdipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain. jmarbones.iacs@aragon.es.
Alejandro Sanz-ParisServicio de Endocrinología y Nutrición, Hospital Universitario Miguel Servet, Zaragoza, Spain. sanzparisalejandro@gmail.com.
Jose Maria ArtigasServicio de Radiodiagnóstico, Hospital Universitario Miguel Servet, Zaragoza, Spain. jmartigasm@gmail.com.
Javier LagosUnidad de Cirugía, Hospital Royo Villanova, Zaragoza, Spain. jlagos@comz.org.
Jose M Arbones-MainarAdipocyte and Fat Biology Laboratory (AdipoFat), Unidad de Investigación Traslacional, Hospital Universitario Miguel Servet, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain. jmarbones.iacs@aragon.es.
Hospital Universitario Miguel Servet · ESServicio Aragonés de Salud · ESHospital Royo Villanova · ESInstituto de Investigación Sanitaria Aragón · ESInstituto de Salud Carlos III · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity is an excessive accumulation of fat frequently, but not always, associated with health problems, mainly type 2 diabetes and cardiovascular disease. During a positive energy balance, as caused by excessive intake or sedentary lifestyle, subcutaneous adipose tissue expands and accumulates lipids as triglycerides. However, the amount of adipose tissue per se is unlikely to be the factor linking obesity and metabolic complications. The expandability hypothesis states that, if this positive energy balance is prolonged, a point is eventually reached where subcutaneous adipose tissue can not further expand and energy surplus no longer can be safely stored. Once the limit on storage capacity has been exceeded, the dietary lipids start spilling and accumulate ectopically in other organs (omentum, liver, muscle, pancreas) forming lipid byproducts toxic to cells. METHODS/

designFATe is a multidisciplinary clinical project aimed to fill gaps that still exist in the expandability hypothesis. Imaging techniques (CT-scan), metabolomics, and transcriptomics will be used to identify the factors that set the limit expansion of subcutaneous adipose tissue in a cohort of caucasian individuals with varying degrees of adiposity. Subsequently, a set of biomarkers that inform the individual limits of expandability will be developed using computational and mathematical modeling. A different validation cohort will be used to minimize the risk of false positive rates and increase biomarkers' predictive performance. DISCUSSION: The work proposed here will render a clinically useful screening method to predict which obese individuals will develop metabolic derangements, specially diabetes and cardiovascular disease. This study will also provide mechanistic evidence that promoting subcutaneous fat expansion might be a suitable therapy to reduce metabolic complications associated with positive energy balance characteristic of Westernized societies.

Indexed as

AdiposityEnergy MetabolismCardiovascular DiseasesDiabetes MellitusDisease ProgressionGene Expression ProfilingGenetic MarkersHumansMetabolomicsObesityPredictive Value of TestsReproducibility of ResultsResearch DesignRisk AssessmentRisk FactorsSpainGenetic Markers

Identifiers

PMID25896263
PMCPMC4409987
OpenAlexW2124593837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.